KR20140028076A - 방사능표지된 글루타미닐 사이클라제 억제제 - Google Patents

방사능표지된 글루타미닐 사이클라제 억제제 Download PDF

Info

Publication number
KR20140028076A
KR20140028076A KR20137033449A KR20137033449A KR20140028076A KR 20140028076 A KR20140028076 A KR 20140028076A KR 20137033449 A KR20137033449 A KR 20137033449A KR 20137033449 A KR20137033449 A KR 20137033449A KR 20140028076 A KR20140028076 A KR 20140028076A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
phenyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20137033449A
Other languages
English (en)
Korean (ko)
Inventor
울리히 헤이서
다니엘 람스벡
한스-울리히 데무스
Original Assignee
프로비오드룩 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로비오드룩 아게 filed Critical 프로비오드룩 아게
Publication of KR20140028076A publication Critical patent/KR20140028076A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR20137033449A 2011-05-27 2012-05-24 방사능표지된 글루타미닐 사이클라제 억제제 Withdrawn KR20140028076A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27
US61/490,654 2011-05-27
PCT/EP2012/059649 WO2012163773A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Publications (1)

Publication Number Publication Date
KR20140028076A true KR20140028076A (ko) 2014-03-07

Family

ID=46149465

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20137033449A Withdrawn KR20140028076A (ko) 2011-05-27 2012-05-24 방사능표지된 글루타미닐 사이클라제 억제제

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG194770A1 (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200144180A (ko) * 2019-06-17 2020-12-29 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140279A1 (en) 2013-03-15 2014-09-18 Probiodrug Ag Novel inhibitors
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT712759A (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
NZ590658A (en) * 2008-07-31 2012-07-27 Probiodrug Ag Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
EP2344157B1 (en) 2008-09-04 2016-05-25 Probiodrug AG Novel inhibitors
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
ES2548913T3 (es) * 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200144180A (ko) * 2019-06-17 2020-12-29 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2014515364A (ja) 2014-06-30
BR112013030341A2 (pt) 2016-11-29
CN103561776A (zh) 2014-02-05
US9610368B2 (en) 2017-04-04
CA2835014A1 (en) 2012-12-06
US8945510B2 (en) 2015-02-03
EA201301334A1 (ru) 2014-05-30
SG10201604304RA (en) 2016-07-28
MX2013013946A (es) 2014-01-31
IL229187A0 (en) 2013-12-31
ZA201308329B (en) 2015-02-25
SG194770A1 (en) 2013-12-30
IL229187A (en) 2017-04-30
US20120301398A1 (en) 2012-11-29
WO2012163773A1 (en) 2012-12-06
EA028533B1 (ru) 2017-11-30
CN103561776B (zh) 2016-08-31
NZ617581A (en) 2016-03-31
US20150104389A1 (en) 2015-04-16
EP2714098A1 (en) 2014-04-09
AU2012264951A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
KR20140028076A (ko) 방사능표지된 글루타미닐 사이클라제 억제제
EP3789380B1 (en) 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting asm activity, and use thereof
RU2376282C2 (ru) Стереоселективный синтез аминокислот для получения изображения опухоли
US20120263646A1 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
HUP0302956A2 (hu) Tioflavinszármazékok az Alzheimer-kór antemortem diagnózisában történő alkalmazásra, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
JPWO2009004914A1 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
JP4554202B2 (ja) 放射性標識神経ペプチドｙｙ５受容体拮抗薬
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US20110217234A1 (en) Imaging ligands
KR20230022470A (ko) 방사성 동위원소가 표지된 바이오틴 유도체 화합물 및 이를 유효성분으로 포함하는 암 진단용 조성물
Bender et al. PET evaluation of the uptake of N-[11C] methyl CP-643,051, an NK1 receptor antagonist, in the living porcine brain
SagsttaS'Transversa Heiser et al.(43) Pub. Date: Nov. 29, 2012
HK1194301B (en) Radiolabelled glutaminyl cyclase inhibitors
HK1194301A (en) Radiolabelled glutaminyl cyclase inhibitors
WO2025225738A1 (ja) がん治療用医薬組成物
Haratake et al. Development of a radioiodinated thioflavin-T-Congo-red hybrid probe for diagnosis of systemic amyloidosis
EP3845541A1 (en) Radioactive imidazothiadiazole derivative compound
NZ617581B2 (en) Radiolabelled glutaminyl cyclase inhibitors
JP2021102593A (ja) タウを画像化する新規化合物
JP2017510566A (ja) 侵害受容処理並びに記憶障害及び認知異常の病態生理学的研究におけるプローブとして高度に選択的なシグマ受容体リガンド及び放射性リガンド
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid